JP2005187405A - Uric acid value inhibitor and purine body adsorbent - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To obtain an uric acid value inhibitor capable of safely inhibiting the increase of an uric acid value in a serum without adverse effect. <P>SOLUTION: The uric acid value inhibitor comprises activated carbon. The above problem is solved by absorbing a purine body which is a causative agent of uric acid contained in foods into the activated carbon in the stomach and intestines to discharge the purine body and reduce the uric acid amount produced by metabolism. It was found that the purine body can selectively be absorbed by using activated carbon surface-treated with a hydrophilic group or a surfactant to complete the present invention. <P>COPYRIGHT: (C)2005,JPO&NCIPI

Description

  The present invention relates to an agent for suppressing the absorption of purine in the body, and in particular, by suppressing the high uric acid level by the above action, for the improvement and prevention of various diseases derived from abnormal uric acid levels such as gout and hyperuricemia. The present invention relates to highly effective preparations, particularly oral pharmaceutical preparations and foods.

  Uric acid is a final metabolite of purine in the human body, and is produced by ingested purine being absorbed and transferred from the stomach and intestine to the body and then oxidized by xanthine oxidase in blood. The physiological solubility of uric acid in the blood is 7 mg / dL, and when the serum uric acid level is 7.0 mg / dL or higher, a high uric acid crystal is diagnosed. When uric acid is present in serum at a high concentration, uric acid crystals are likely to precipitate, and gout that develops due to the accumulation of precipitates in joints is well known to be accompanied by severe pain. In recent years, it has also been pointed out that serious damage is caused to the heart, kidneys and the like other than the tissues around the joints.

  Conventionally, there were not so many patients with gout and hyperuricemia in Japan, but with the change of eating habits to the Western type, the number of people who eat meals mainly with meat containing a large amount of purines is increasing. Furthermore, the incidence of gout is increasing with increasing stress, and interest in prevention and treatment of hyperuricemia is increasing.

  In general, when the uric acid level is 8.5 mg / dL or more in men and 7.5 mg / dL in women, the risk of gout is greatly increased, so the serum uric acid level is decreased by drugs, diet, etc. Treatment to let you be done. In drug therapy, for example, a uric acid excretion promoter and a synthesis inhibitor are used as a uric acid level lowering agent. Among them, allopurinol, which inhibits the action of xanthine oxidase, is used for the treatment of gout as the only known uric acid synthesis inhibitor (Nippon Clinical, Nippon Clinic, pages 1081-1085, 1991: non-patented). Reference 1).

  However, allopurinol has been found to cause severe rashes such as mucocutaneous ocular syndrome, toxic epidermal necrosis, exfoliative dermatitis, fever, lymphadenopathy, liver damage, renal function abnormalities, etc. Collection of pharmaceuticals, Jiho, pages 184-185, 2003: Non-patent document 2). In particular, when renal dysfunction is present, oxypurinol accumulates and accumulates at a high concentration in the body, so it is necessary to reduce the dose of allopurinol (diagnosis and treatment, diagnosis and treatment company, page 246, 2002: Non-patent document 3). ).

  By the way, purines are contained in many foods and are taken into the body by eating and drinking. Alcoholic beverages such as beer and liquor, liver, liver liver, beef steak, bonito fillets, etc. contain particularly a large amount of purine, and there is a concern about an increase in uric acid levels due to excessive intake. However, since the purine body greatly affects the taste of food and drink, it is not easy to reduce it without impairing palatability.

  Under such circumstances, a uric acid level inhibitor / lowering agent with fewer side effects is required, and further, a preparation for maintaining normal uric acid level normally has been desired. For example, JP 2001-163788 (Patent Document 1) proposes a purine digestion / absorption regulator for humans containing chitosan. However, the ability of chitosans to adsorb purines is not always sufficient, and the effect is not sufficient when the absorption rate is high, such as purines that are ingested with alcohol such as beer and happoshu.

On the other hand, activated carbon is used as various adsorbents and is also known as medicinal charcoal in the pharmaceutical field, and is used for detoxification against acute poisoning of poisonous substances and harmful substances. Moreover, activated carbon is used as an anti-obesity agent (Japanese Patent Laid-Open No. 11-29485: Patent Document 2), an anti-diabetic agent (Japanese Patent Laid-Open No. 6-298653: Patent Document 3), and an anti-inflammatory bowel disease agent (Japanese Patent Laid-Open No. 8-40918: Patent Document 4). ), An anti-manic disease agent (Japanese Patent Laid-Open No. Hei 8-40919: Patent Document 5) has been proposed. However, there is no example used for the purpose of adsorbing purine and suppressing absorption in the body, and the effect and utilization as a uric acid level inhibitor are not yet known.
Japanese Clinical, Nippon Clinic, 1081-1085, 1991 Japanese Medicine Collection, Jiho, pages 184-185, 2003 Diagnosis and treatment, Diagnosis and treatment company, page 246, 2002 JP 2001-163788 A JP-A-11-29485 JP-A-6-298653 JP-A-8-40918 JP-A-8-40919

  The present invention provides a uric acid level inhibitor that reduces the amount of purine absorbed in the body, thereby suppressing an increase in serum uric acid level, and is excellent in safety. An object is to provide oral preparations such as oral medicines and health foods useful for prevention or treatment.

As a result of the study, the present inventors have found that activated carbon efficiently adsorbs purine, which is contained in foods and is a causative substance of uric acid, and converts the purine to activated carbon before being absorbed into the body from the gastrointestinal mucosa. The present inventors have found that the above-mentioned problems can be solved without side effects by adsorbing and discharging the substance as it is and not allowing it to be absorbed into the body, resulting in the present invention. Moreover, it discovered that a purine body could be selectively adsorbed by using activated carbon surface-treated with a hydrophilic group or a surfactant, and completed the present invention. That is, the present invention
<1>
A uric acid level inhibitor characterized by containing activated carbon.
<2>
The uric acid level inhibitor according to <1>, wherein the weight average particle diameter of the activated carbon is 0.001 μm or more and 200 μm or less.
<3>
The average pore diameter of activated carbon is 1 to 10 nm, The uric acid value inhibitor according to <1> to <2>.
<4>
The uric acid value inhibitor according to <1> to <3>, wherein the activated carbon is activated carbon modified with a hydrophilic group.
<5>
The uric acid value inhibitor according to <1> to <4>, wherein the activated carbon is activated carbon treated with a surfactant.
<6>
The uric acid level inhibitor according to <5>, wherein the surfactant is one or more selected from nonionic active agents and amphoteric active agents.
<7>
An oral pharmaceutical composition comprising the uric acid level inhibitor of <1> to <6>.
<8>
The composition for eating and drinking containing the uric acid value inhibitor of <1>-<6>.
<9>
A purine adsorbent characterized by containing activated carbon.
<10>
A composition for suppressing purine absorption in a human body, comprising the purine adsorbent according to <9>.
I will provide a.

  According to the present invention, purine bodies contained in foods and the like are adsorbed on activated carbon, which is the active ingredient of the present invention, and discharged outside the body before absorption in the gastrointestinal tract, thereby suppressing an increase in serum uric acid level. As a result, the effect of preventing and improving diseases caused by abnormal uric acid levels such as hyperuricemia and gout can be obtained. In particular, when activated carbon having an average particle diameter of 0.001 μm to 200 μm and an average pore diameter of 1 to 10 nm is used, the purine body adsorption effect is high and the uric acid value suppressing effect is particularly excellent. Moreover, the purine body selective adsorption effect is acquired by processing the activated carbon surface with a hydrophilic group or surfactant. Therefore, oral preparations using this, especially oral medicines and foods and drinks, are useful for the prevention / amelioration of diseases caused by abnormal uric acid levels and the maintenance of normal uric acid levels.

  The activated carbon used in the present invention is a component that is orally administered and adsorbs the purine body in the gastrointestinal tract, and is suitable for food and medicine. Activated carbon is porous carbon particles having innumerable fine pores inside, and the pore structure usually consists of micropore passages communicating with each other.

  In general, activated carbon is produced by carbonizing and activating vegetable fibers such as wood and coconut shells, and organic materials such as petroleum (including synthetic resins obtained from petroleum) and coal. As the activated carbon used in the present invention, any of the above raw materials can be used as long as the safety is not impaired. However, activated carbon using coconut shells or petroleum as a raw material, which is known to be safe when ingested as a food, is preferable.

  Carbonization is a process in which carbon or oxygen contained in the activated carbon raw material is heated in an inert gas atmosphere to remove a part of volatile matter to obtain a carbide. The lower limit of the heating temperature is 200 to 800 ° C. The temperature is preferably 400 ° C to 800 ° C. When heated at 200 ° C. or lower, carbonization may be insufficient, and the final activated carbon may contain a large amount of impurities. When heated above 1000 ° C., the amount of adsorbed purine bodies decreases and the effect of the present invention decreases. There is a fear.

  Activation is a step of imparting a fine structure to the carbide obtained above, and gas activation methods and chemical activation methods are known. In the gas activation method, the microstructure is developed by volatile components and carbon molecules in the carbide by heating at several hundreds of degrees Celsius for several hours to several hours in a gas atmosphere such as oxygen, water vapor, carbon dioxide, or air as an activator. Let The heating temperature at this time is appropriately selected from 700 ° C. to 1000 ° C. depending on the type of raw material and the type and concentration of gas, and more preferably 800 ° C. or higher and 950 ° C. or lower. Below 800 ° C, the development of the fine structure is insufficient and the amount of adsorbed purine bodies may be reduced. When the temperature is 1000 ° C or higher, the surface area of the activated carbon is reduced and the adsorbed amount of purine bodies is reduced. The rate may be worse. Further, the heating time is appropriately selected depending on the type of raw material to be used, but is 5 minutes to 5 hours, more preferably 10 minutes to 3 hours. When activated in this range, an excellent uric acid level inhibitor having a high yield and a high adsorbed amount of purine can be obtained. On the other hand, the chemical activation method uses zinc chloride, iron chloride, calcium phosphate, calcium hydroxide, magnesium carbonate, potassium carbonate, sulfuric acid, etc. instead of oxygen and water vapor used in the gas activation method as an activator, and with hydrochloric acid. It is activated by washing, adjusting the pH with an alkaline aqueous solution and drying.

  The average pore diameter of the activated carbon used in the present invention is preferably from 0.1 nm to 100 nm, more preferably from 0.5 nm to 50 nm, still more preferably from 1 nm to 20 nm. Within this range, the amount of adsorbed purine is particularly good, and the uric acid level suppressing effect is also excellent. This is presumed to be because the purine body is adsorbed efficiently and the desorption is small. The average pore diameter can be determined from, for example, a pore diameter distribution calculated by Cranston-Inkley method, Molecular-Probe method, Dollimore-Heal method, etc. by measuring nitrogen adsorption / desorption isotherm.

  The average particle size of the activated carbon used in the present invention is 0.01 μm or more and 200 μm or less, more preferably 0.1 μm or more and 100 μm or less. Within this range, the preparation of the present invention having particularly good dosing properties and the effects of the present invention can be obtained. The average particle diameter is measured by, for example, an optical microscope method, a sieving method (both described in the 14th revised Japanese Pharmacopoeia manual), a laser diffraction particle size distribution measuring device, or the like.

  The activated carbon of the present invention preferably uses a surface whose surface is chemically modified with a hydrophilic group or a surface treated with a surfactant. The activated carbon that has been subjected to the above treatment imparts purine body selective adsorptivity, so even when ingested with food, it does not impair the effect of suppressing uric acid levels, and suppresses adsorption of nutrient components such as fat-soluble vitamins, for example. Therefore, it is possible to absorb these in the body.

  Examples of the hydrophilic group to be chemically modified include acidic groups such as sulfuric acid group, phosphoric acid group, carboxyl group, phenolic hydroxyl group, nitro group, lactone and carboxylic anhydride, amino group, chromene structure, pyrone-like structure and the like. Neutral groups such as a functional group, a carbonyl group, a quinone type carbonyl group, and a cyclic peroxide can be used. Among these, acidic groups are preferable because the adsorbability of the basic purine body is particularly good. The degree (amount) of the modifying group is preferably 0.1 to 10 meq / g.

  The method of chemical modification is not particularly limited, but it may be introduced at the time of producing activated carbon or after modification.

  When a modifying group is introduced during the production process of activated carbon, it may be added, for example, as an activation gas in an activation process during activated carbon production. That is, activation is performed by mixing a modification gas such as sulfuric acid, phosphoric acid, carbonic acid, or ammonia in an activation gas such as water vapor, carbon dioxide, or air. Alternatively, during the activation step, the carbonized intermediate can be activated by spraying a solution containing a modifying group ion such as sulfuric acid, phosphoric acid, carbonic acid, or ammonia.

  The surfactant used for the surface treatment with the surfactant is not particularly limited as long as it can hydrophilize the activated carbon surface, such as a nonionic surfactant, an anionic surfactant, a cationic surfactant, and an amphoteric surfactant. Nonionic activators include polyoxyethylene alkyl ether, polyoxyethylene alkylphenyl ether, polyoxyethylene polyoxypropylene alkyl ether, polyoxyethylene (cured) castor oil, polyoxyethylene glycerin fatty acid ester, polyglycerin fatty acid ester, sorbitan Fatty acid ester, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene sorbite fatty acid ester, polyoxyethylene sterol, hydrogenated sterol, polyethylene glycol fatty acid ester, polyoxyethylene lanolin, polyoxyethylene lanolin alcohol, polyoxyethylene beeswax derivative, polyoxy Ethylene alkylamine, polyoxyethylene fatty acid amide, alkyldiethanolamine, Alkyl glucoside, alkyl maltoside, alkyl polyglucoside, fatty acid sucrose ester, methyl glucoside ester, methyl glucamide, alkyl anion carboxylate, N-acyl sarcosine salt, N-acyl glutamate, N-acyl N-acyl amino acid salts such as -N-methyl β-alanine salt, alkyl polyoxyethylene sulfate, α-olefin sulfonate, N-acyl-N-methyl taurate, alkyl sulfosuccinate, alkyl phosphate, Polyoxyethylene alkyl ether phosphate, N-acylaminoethyljetylamine salt, N-acylguanidine salt as cationic activator, (hydrogenated) soybean phospholipid, (hydrogenated) egg yolk phospholipid as amphoteric activator , Lecithin such as phosphatidylcholine Conductor, N-alkyldimethylamine oxide, N-alkyl-β-iminobipropionate, N-alkyldimethylbetaine, N-acyl-dimethylbetaine, N-acylamidopropyldimethylbetaine, 2-alkylimidazoline derivative, N- Examples thereof include alkylsulfobetaine glucamine and N-alkylcarboxybetaine glucamine. From the viewpoint of purine adsorption effect, anionic surfactants, nonionic surfactants, and amphoteric surfactants are preferred, and from the viewpoint of internal use, nonionic surfactants and amphoteric surfactants are preferred. In particular, nonionic surfactant, (hydrogenated) egg yolk phospholipid, and (hydrogenated) soybean phospholipid are preferable.

  Surface modification with a surfactant involves dissolving or dispersing the above surfactant in water or a solvent such as lower alcohol, then adding activated carbon, mixing and stirring, washing excess surfactant with water, and drying the activated carbon. Surface modification can be performed.

  The ratio of the surfactant to the activated carbon is not particularly limited, but is 0.0001 to 100 times, preferably 0.001 to 50 times, more preferably 0.005 to 20 times. In this range, a purine adsorbent having a particularly excellent selective adsorptivity, that is, a uric acid level inhibitor can be obtained.

  In the present invention, by taking activated carbon, the purine body is adsorbed to the activated carbon in the gastrointestinal tract before being absorbed into the body, and is directly discharged out of the body through the digestive organ, thereby suppressing the digestion and absorption of the purine body. As a result, an increase in the uric acid level is suppressed, and the continuous use is effective in improving the high uric acid level. From the viewpoint of the effect, it is preferable to adjust the dose of activated carbon so that the daily intake is about 0.01 to 100 g. In addition, it is preferably taken before or during a meal.

  The activated carbon that is the uric acid level inhibitor (or purine adsorbent) of the present invention can be taken as it is in powder form with water or the like, but the activated carbon has a problem that it feels rough and the mouth becomes black. is there. Therefore, for the purpose of facilitating administration, the pharmaceutical oral composition containing the activated carbon of the present invention is used. For example, drinks (including suspensions), gummi, capsules, jellies, solid preparations (tablets, granules) It is preferable to use various processed preparation forms such as At that time, in the case of a solid material, it is preferable to use a coating agent. Furthermore, various additives such as sweeteners, flavoring agents, coloring agents, excipients, binders, disintegrants, or suspending agents may be blended into various processed preparations as long as the effects of the present invention are not impaired. it can. The blending amount of the activated carbon can be appropriately set so as to achieve the desired intake amount.

  Moreover, it is also preferable to set this invention as the food-drinks composition which mix | blended the activated carbon of this invention. Examples of the food and drink include noodles, bread, confectionery, kneaded products, dairy products, prepared dishes, soups, beverages, granules, and the like. The blending amount of the activated carbon can be appropriately set so as to achieve the desired intake amount.

  In the present specification, the purine body refers to a compound having the structure of purine or a purine derivative, unless otherwise specified. Purine bodies as used herein include purine bases (eg, adenine, guanine), purine nucleosides (adenosine, guanosine, inosine), purine nucleotides (adenylic acid, guanylic acid, inosinic acid), and small or high molecular nucleic acids (eg, Oligonucleotides, polynucleotides), but are not limited thereto.

  EXAMPLES Hereinafter, although an Example and a comparative example are shown and this invention is demonstrated concretely, this invention is not restrict | limited to the following Example.

<Test 1> Adsorption amount of purine bodies in aqueous solution Adenosine, which is a basic purine contained in a large amount in beer as a purine body, was adjusted to an aqueous solution of 100 mg / L. As a result of measuring the absorbance of this aqueous solution with an ultraviolet / infrared absorptiometer, a maximum of absorption was observed in the vicinity of 260 nm. Furthermore, since the absorbance at 260 nm was in a relationship between the adenosine concentration and the linear regression line, the concentration of adenosine was calculated from the absorbance.
To 100 mL of the above adenosine aqueous solution, 100 mL of a 400 mg / L dispersion aqueous solution of activated carbon (medicine charcoal, manufactured by Oriental Pharmaceutical Co., Ltd.), 100 mL was added, stirred for 5 minutes, filtered, and the absorbance of the filtrate was measured. The results are shown in Table 1. The pH of the aqueous solution was adjusted to 1.2 from hydrochloric acid / sodium chloride (a solution obtained by dissolving 2.0 g of sodium chloride in 7.0 mL of hydrochloric acid and water to make 1000 mL). The amount of adenosine adsorption was determined by the following formula.

Adsorption amount (%) =
{(Absorbance of control−absorbance of sample) / (absorbance of control)} × 100

  From the results of Table 1, it was found that most of the purine adenosine was adsorbed on the activated carbon by adding the activated carbon. Furthermore, as a kind of activated carbon, it became clear that the activated carbon with an average particle diameter of 20-30 micrometers is more preferable.

<Test 2> Measurement of serum uric acid level at the time of oral loading of purine body It was examined how the uric acid level in serum was changed by administering activated carbon in the state where the purine body was orally administered and given a load. As a method, 5-week-old male Wistar rats (average body weight 102 g) were used, and 100% malt beer was used as a purine to be administered orally. The rats were divided into two groups: a group in which only 10 mL of beer was ingested, and a group in which 10 mg of beer was ingested immediately after administration of 0.5 mg of activated carbon (medicinal charcoal, manufactured by Oriental Pharmaceutical Co., Ltd.), and blood was collected before ingestion and 90 minutes after ingestion. The uric acid level in serum was measured. The test results are shown in Table 2. The rate of change of the uric acid value was determined from the following formula.

Rate of change in uric acid level (%) =
(Uric acid value 90 minutes after ingesting beer / Uric acid value before ingesting beer) × 100

  From the results in Table 2, serum activated uric acid levels were significantly suppressed by administering activated carbon after a beer-ingested meal compared to the non-administered group. This is considered to be a result of suppressing absorption by purine bodies such as adenosine contained in beer adsorbed on activated carbon.

(Example 1) Oral solid preparation component name Compounding amount (mg / tablet)
Activated carbon (medicinal charcoal, manufactured by Oriental Pharmaceutical Co., Ltd.) 100.0
Crystalline cellulose (Avicel PH-302, manufactured by Asahi Kasei Corporation) 90.0
pregelatinized starch (degree of gelatinization 84.6%, PCS, manufactured by Asahi Kasei Corporation) 35.0
Anhydrous lactose (DMV lactose 200 mesh, manufactured by DMV) 25.0
Total 250.0
An internal solid preparation having the above composition was produced according to a conventional method to obtain tablets having an average mass of 250.0 mg and a diameter of 9 mm.

Example 2 Capsule
Ingredient name Compounding amount (mg / capsule)
Activated carbon (medicinal charcoal, manufactured by Oriental Pharmaceutical Co., Ltd.) 100.0
Ethylcellulose (Etocel, manufactured by Dow Chemical Company) 20.0
The above ingredients were mixed and filled into gelatin soft capsules by a conventional method to obtain the product of the present invention.

(Example 3) Name of component for internal use liquid compounding amount (mg / 1 60 mL)
Activated carbon (medicinal charcoal, manufactured by Oriental Pharmaceutical Co., Ltd.) 200.0
Sucrose (reducing sugar ratio 0.03 mass%, manufactured by Shin Mitsui Sugar Co., Ltd.) 20000.0
D-sorbitol (70%, manufactured) 500.0
Sodium citrate 400.0
Citric acid 300.0
Sodium hydroxide Appropriate amount of hydrochloric acid Appropriate amount of purified water The rest The internal liquid preparation having the above composition was produced according to a conventional method to obtain the product of the present invention.

(Example 4) Chocolate component name Compounding amount (mg / 1 formulation 3g)
Activated carbon (medicinal charcoal, manufactured by Oriental Pharmaceutical Co., Ltd.) 100.0
Cocoa butter alternative oil (melting point 29 ° C) 1000.0
Cocoa powder (18% ether extract, 5% ash) 650.0
Powdered reduced maltose water candy 1233.5
Soy lecithin 15.0
Vanillin 1.5
Activated charcoal, cocoa butter substitute fat and oil, cacao powder and powdered reduced maltose water candy were pulverized at about 50 ° C. with a ball mill, and soybean lecithin and vanillin were added to the pulverized product and mixed. 3 g of the obtained liquid having viscosity was dispensed into a polypropylene blister package and sealed with an aluminum film to obtain a product of the present invention.

(Example 5) Chocolate hung confectionery Chocolate made of the composition of Example 4 is heated to about 50 ° C. to make it liquid, and 3 g of a commercially available bar-shaped baked confectionery (Pretz Roast, manufactured by Glico Co., Ltd.) is hung. The product of the present invention was obtained by cooling.

<Test 3> Effect of activated carbon modified with egg yolk phospholipid (1) Preparation of activated carbon modified with egg yolk phospholipid 0.2 g of egg yolk phospholipid (Resinol Y-10E, manufactured by Nikko Chemicals) was dissolved in 100 mL of ethanol and activated carbon (medicinal charcoal) , Manufactured by Oriental Pharmaceutical Co., Ltd., stirred for 1 hour at room temperature, filtered, washed with 100 mL of pure water and dried under reduced pressure (ratio of yolk phospholipid to activated carbon: 0 .01).

(2) Adsorption rate of fat-soluble vitamin in aqueous solution Adsorption test was conducted on d-α-tocopherol acetate, which is a typical fat-soluble vitamin, under the same conditions and methods as those for purine (adenosine) adsorption in <Test 1>. (A sample solution of adenosine and d-α-tocopherol acetate were prepared at 100 mg / L). As for the amount of d-α-tocopherol acetate in the aqueous solution, the adsorption rate was determined by the HPLC method using a non-activated carbon treatment as a control. The results are shown in Table 3.

  From the results in Table 3, medicinal charcoal (activated carbon that has not been surface-modified) adsorbs both purine bodies and d-α-tocopherol acetate, which is a fat-soluble vitamin, whereas activated carbon that has been surface-modified absorbs fat. It was revealed that the adsorption rate of soluble vitamins decreased and the adsorption selectivity for purines increased.

(3) Measurement of serum uric acid level at the time of oral loading of purine (human)
We examined how the uric acid level in serum changed by administering surface-modified activated carbon in a state in which purine was orally administered and loaded. The method is that three male volunteers (33-36 years old) with high uric acid levels take 10 mL of 100% malt beer per kg of body weight, and one week later, the same volunteer is subjected to surface modification with beer under the same conditions. In the case of sequentially ingesting 0.1 g of activated charcoal encapsulated in gelatin soft capsules, blood is collected before ingestion and 90 minutes after ingestion, uric acid level in serum is measured using a commercially available measurement kit, and the rate of change is determined. Calculated. The test results (average value) are shown in Table 4. The rate of change of the uric acid value was determined from the following formula.

Rate of change in uric acid level (%) =
(Uric acid value 90 minutes after ingesting beer / Uric acid value before ingesting beer) × 100

  From the results shown in Table 4, by administering the surface-modified activated carbon after the beer intake meal, the increase in serum uric acid level was suppressed as compared with the non-administered group. This is considered to be a result of suppressing the absorption of purine bodies by adsorbing the purine bodies such as adenosine contained in beer on the surface-modified activated carbon.

(Example 6) Oral solid preparation component name Compounding amount (mg / tablet)
Activated carbon modified with sulfonic acid group ^{* 1} 100.0
Crystalline cellulose (Avicel PH-302, manufactured by Asahi Kasei Corporation) 90.0
pregelatinized starch (degree of gelatinization 84.6%, PCS, manufactured by Asahi Kasei Corporation) 35.0
Anhydrous lactose (DMV lactose 200 mesh, manufactured by DMV) 25.0
Total 250.0
An internal solid preparation having the above composition was produced according to a conventional method to obtain tablets having an average mass of 250.0 mg and a diameter of 9 mm.
* 1: Activated carbon chemically modified with sulfonic acid groups:
Average particle size 30 μm, wood-based sawdust, sulfonic acid loading 1.0 meq / g

(Example 7) Capsule component name Compounding amount (mg / capsule)
Egg yolk phospholipid modified activated carbon ^{* 1} 100.0
Ethylcellulose (Etocel, manufactured by Dow Chemical Company) 20.0
The above ingredients were mixed and filled into gelatin soft capsules by a conventional method to obtain the product of the present invention.
* 1: Activated carbon modified with egg yolk phospholipid:
Prepared in Example 5

(Example 8) Oral liquid component name Compounding amount (mg / 1 bottle 60 mL)
Activated carbon modified with sulfonic acid group ^{* 1} 200.0
Sucrose (reducing sugar ratio 0.03 mass%, manufactured by Shin Mitsui Sugar Co., Ltd.) 20000.0
D-sorbitol (70%, manufactured) 500.0
Sodium citrate 400.0
Citric acid 300.0
Sodium hydroxide Appropriate amount of hydrochloric acid Appropriate amount of purified water The rest The internal liquid preparation having the above composition was produced according to a conventional method to obtain the product of the present invention.
* 1: Activated carbon chemically modified with sulfonic acid groups:
Average particle size 30 μm, wood-based sawdust, sulfonic acid loading 1.0 meq / g

(Example 9) Chocolate component name Compounding amount (mg / 1 formulation 3 g)
Egg yolk phospholipid modified activated carbon ^{* 1} 100.0
Cocoa butter alternative oil (melting point 29 ° C) 1000.0
Cocoa powder (18% ether extract, 5% ash) 650.0
Powdered reduced maltose water candy 1233.5
Soy lecithin 15.0
Vanillin 1.5
Activated charcoal, cocoa butter substitute fat and oil, cacao powder and powdered reduced maltose water candy were pulverized at about 50 ° C. with a ball mill, and soybean lecithin and vanillin were added to the pulverized product and mixed. 3 g of the obtained liquid having viscosity was dispensed into a polypropylene blister package and sealed with an aluminum film to obtain a product of the present invention.
* 1: Activated carbon modified with egg yolk phospholipid: prepared in Example 5

(Example 10) Chocolate hung confectionery Chocolate made of the composition of Example 9 is heated to about 50 ° C. to form a liquid, and is multiplied by 3 g of one commercially available bar-shaped baked confectionery (Pretz Roast, manufactured by Glico Co., Ltd.) The product of the present invention was obtained by cooling.

Claims (10)

A uric acid level inhibitor characterized by containing activated carbon. The uric acid level inhibitor according to claim 1, wherein the activated carbon has a weight average particle diameter of 0.001 µm or more and 200 µm or less. The uric acid value inhibitor according to claim 1, wherein the activated carbon has an average pore diameter of 1 to 10 nm. The uric acid level inhibitor according to claim 1, wherein the activated carbon is activated carbon modified with a hydrophilic group. The uric acid value inhibitor according to claim 1, wherein the activated carbon is activated carbon treated with a surfactant. The uric acid level inhibitor according to claim 5, wherein the surfactant is one or more selected from a nonionic active agent and an amphoteric active agent. An oral pharmaceutical composition comprising the uric acid level inhibitor according to claim 1. A composition for eating and drinking, comprising the uric acid level inhibitor according to claim 1. A purine adsorbent characterized by containing activated carbon. A composition for suppressing purine absorption in a human body, comprising the purine adsorbent according to claim 9.